Please login to the form below

Not currently logged in
Email:
Password:

BMS melanoma drug meets goal

Bristol-Myers Squibb has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study

Bristol-Myers Squibb (BMS) has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study.

The trial, known as study 024, showed that ipilimumab improved overall survival in previously untreated patients with unresectable stage III or stage IV melanoma. The trial compared the BMS drug in combination with dacarbazine chemotherapy to the chemotherapy regimen alone.

BMS said it plans to submit an abstract of the data to the American Society of Clinical Oncology for presentation at the society's Annual Meeting this summer.

BMS has already filed the drug with the US Food and Drug Administration (FDA), as well as regulatory authorities in a number of other countries, as a therapy for previously treated unresectable stage III or stage IV melanoma patients. In the US, a decision regarding the drug for that indication is due within days.

22nd March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics